Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease
Status:
Unknown status
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
Lovaza is the only fish oil supplement approved by the FDA. It is available by prescription
for the treatment of hypertriglyceridemia (> 500 mg/dl). The primary mechanism appears to be
a reduction in hepatic production of triglycerides. Also decreases the hepatic production of
very low density lipoprotein (VLDL). There also may be antioxidant properties as well. The
thought behind using Lovaza as a treatment for non-alcoholic fatty liver disease (NAFLD) is
two fold. It would help in the decrease production of triglycerides by the liver and have
antioxidant properties decreasing the production of free radicals in the liver. In doing so,
steatohepatitis, fibrosis, and perhaps cirrhosis and liver cancer would be prevented.